Can diet and natural approaches help manage Crohn's disease?

Unlike ulcerative colitis (where smoking has a paradoxical protective effect), Crohn's disease is dramatically worsened by tobacco. Active smokers develop more aggressive disease, require surgery sooner, relapse faster after surgery, and respond less well to immunosuppressive therapy. The landmark long-term cohort study by Cosnes and colleagues reviewed the medical charts of 400 consecutive patients with Crohn's disease and found that smokers required more glucocorticoids and immunosuppressive drugs, and that the surgical rate rose significantly in 19 patients who started smoking after diagnosis and fell significantly in 34 who stopped, compared with matched controls¹. A 2006 meta-analysis pooling data across multiple studies confirmed that current smoking approximately doubles the risk of developing Crohn's disease and approximately doubles the risk of recurrence after surgery².

Quitting appears to reverse part of this risk: in the Cosnes cohort, the surgical rate decreased significantly in the 34 patients who stopped smoking, compared with matched controls¹. For anyone with Crohn's who still smokes, cessation is arguably the single most cost-effective intervention available.

Vitamin D — More Than Just a Bone Vitamin

Vitamin D modulates innate and adaptive immunity, supports intestinal barrier integrity through tight-junction protein expression, and is widely deficient in Crohn's patients due to malabsorption from inflamed small bowel and avoidance of fortified dairy. A 2010 Danish double-blind randomized controlled trial gave 94 Crohn's patients in remission either 1200 IU/day vitamin D3 or placebo for 12 months. Relapse rate was 13% in the vitamin D group versus 29% in the placebo group, a difference that approached statistical significance (p=0.06) despite the modest sample size⁵. Subsequent observational cohorts have consistently shown that low serum 25-hydroxyvitamin D is associated with higher disease activity, more frequent relapses, and increased need for surgery.

A reasonable target for most Crohn's patients is a serum 25(OH)D level of 40–60 ng/mL (100–150 nmol/L). Achieving this typically requires 2,000–5,000 IU/day of vitamin D3, sometimes more in active malabsorption. Always pair high-dose vitamin D with vitamin K2 to direct calcium into bone rather than soft tissue.

See our Vitamin D Supplementation page for dosing details and our Vitamin K2 page for the calcium-routing rationale.

Exclusive and Partial Enteral Nutrition

Exclusive enteral nutrition (EEN) — replacing all food with a polymeric or elemental liquid formula for 6 to 8 weeks — is the only therapy that consistently induces both clinical remission and mucosal healing in pediatric Crohn's disease without the side effects of corticosteroids. The Borrelli 2006 randomized trial in 37 children with active Crohn's compared 10 weeks of polymeric diet to oral corticosteroids and found similar clinical remission rates (79% with diet vs 67% with steroids), but mucosal healing on follow-up endoscopy was significantly higher in the diet group³. EEN is now first-line therapy for pediatric Crohn's in European and many North American guidelines.

EEN is difficult for most adults to follow long-term because it means giving up all regular food. The Crohn's Disease Exclusion Diet (CDED), developed by Israeli pediatric gastroenterologist Arie Levine, combines partial enteral nutrition with a structured whole-food diet that excludes specific dietary triggers (animal fat, gluten, emulsifiers, processed foods, certain dairy components) thought to drive dysbiosis and barrier dysfunction. The 2014 open-label cohort showed 70% of children and young adults achieved remission on CDED plus partial enteral nutrition⁶. The 2019 randomized controlled trial in 78 children with mild-to-moderate Crohn's compared CDED + PEN to traditional EEN. By week 6, both arms achieved similar high remission rates (75% vs 59%), but tolerance was dramatically better with CDED + PEN (97% vs 73%), and remission was sustained at week 12 in significantly more CDED patients⁷. The CDED is now a credible whole-food alternative to EEN with strong RCT support.

Omega-3 Fatty Acids — Practical Inflammation Lowering, Not Drug Replacement

Fish oil supplies EPA and DHA, which compete with arachidonic acid in cell membranes and produce less inflammatory eicosanoids and pro-resolving lipid mediators (resolvins, protectins). For maintaining remission, the evidence is mixed. The 2014 Cochrane systematic review by Lev-Tzion and colleagues pooled six randomized trials with 1,039 Crohn's patients and concluded that omega-3 fatty acids "are probably ineffective for maintenance of remission" with a small absolute benefit that did not reach clinical significance once the two large EPIC trials were included⁴.

This does not mean omega-3 is useless in Crohn's. It does mean fish oil should not replace proven maintenance medication. Higher intake of EPA and DHA — through fatty fish like wild salmon, sardines, mackerel, and anchovies — is associated with lower IBD risk in observational data and remains a sound part of an anti-inflammatory dietary pattern. See our Omega-3 EPA and DHA page for sources and dosing.

Diet Patterns That Reduce Risk and Activity

A 2011 systematic review of 19 studies on diet and IBD risk found consistent associations: high intake of saturated fat, total fat, polyunsaturated omega-6 fats, and meat were associated with increased risk of developing Crohn's disease, while high intake of fiber, fruits, and vegetables was associated with reduced risk⁸. Animal protein in particular — especially from processed meats — was a recurring risk signal across studies.

The dietary pattern with the most evidence for both prevention and management overlaps with what we recommend across this site:

• Mediterranean-style eating — vegetables, fruits, legumes, whole grains, olive oil, fatty fish, modest dairy, minimal red and processed meat
• Avoid emulsifiers and ultra-processed foods — carboxymethylcellulose, polysorbate-80, and other emulsifiers used in processed foods alter the mucus layer and gut microbiota in ways implicated in IBD pathogenesis
• Limit refined sugar and refined carbohydrate — associated with higher disease activity in observational cohorts
• Identify personal trigger foods — many Crohn's patients have specific intolerances (lactose, fructose, sorbitol, certain fibers during flares) that are individual rather than universal

During active flares, a low-residue or low-fiber approach may temporarily reduce mechanical irritation; this is different from the high-fiber pattern recommended in remission. Work with a dietitian familiar with IBD when planning major changes.

The Microbiome Angle

Crohn's disease is associated with reduced microbial diversity, lower abundance of Faecalibacterium prausnitzii (a major butyrate producer with anti-inflammatory properties), and expansion of pro-inflammatory taxa including some adherent-invasive Escherichia coli. Probiotic supplementation alone has not produced consistent benefit in Crohn's randomized trials, in contrast to the clearer benefits seen in pouchitis and ulcerative colitis. The more promising microbiome interventions in Crohn's are dietary — feeding the existing microbiome with fermentable fibers and polyphenols rather than adding outside organisms.

See our Gut Microbiome page and Butyrate page for the broader gut-health context.

Other Nutraceuticals With Suggestive Evidence

• Curcumin — small RCTs in ulcerative colitis show benefit as add-on therapy; Crohn's evidence is weaker but mechanistic plausibility is high. See our Curcumin page
• Boswellia serrata — a 2001 randomized, double-blind trial in active Crohn's disease (102 patients randomized) found the Boswellia serrata extract H15 not inferior to mesalazine on the change in Crohn's Disease Activity Index, though the drop in score was not significantly greater with H15⁹. See our Boswellia page
• Zinc — often deficient in Crohn's; low zinc impairs intestinal barrier function and immune regulation. See our Zinc page
• Iron — anemia is common; iron deficiency should be corrected, but oral iron can worsen gut inflammation. Many Crohn's patients require IV iron under medical supervision

These are adjuncts, not replacements for prescribed therapy in active disease.

Smoking and Crohn's Disease — The Cosnes Cohort

Cosnes and colleagues (1996, PMID 8566589, Gastroenterology) reviewed the medical charts of 400 consecutive patients with Crohn's disease whose smoking habits were specified by direct interview, examining the effects of smoking on the long-term course of the disease and its relationship to therapy. Frequency and extent of excisional surgery were not significantly different in smokers and nonsmokers, but smokers required more glucocorticoids and immunosuppressive drugs. The effect of smoking on the need for immunosuppressive drugs was dose-dependent and was significant in women but not in men: for female smokers, the 10-year risk of immunosuppressive therapy was 52% compared with 24% for nonsmokers (P < 0.001). The risk of surgery increased only in patients who smoked and did not take immunosuppressive drugs, and the surgical rate increased significantly during smoking in 19 patients who started smoking after diagnosis and decreased significantly in 34 patients who stopped, compared with matched controls. The authors concluded that patients who smoke, particularly women and heavy smokers, run a high risk of developing severe disease, while immunosuppressive therapy neutralizes the influence of smoking on surgical rates. This work, along with later replications, made smoking cessation a standard recommendation in every modern Crohn's guideline.

Smoking — Pooled Meta-Analysis

Mahid et al. (2006, PMID 17120402, Mayo Clinic Proceedings) systematically reviewed observational studies on smoking and IBD, pooling data from multiple cohorts to derive overall risk estimates. For Crohn's disease, current smoking was associated with an odds ratio of approximately 1.76 (95% CI 1.40-2.22) for disease development compared to non-smokers, and former smokers had an odds ratio of approximately 1.30 (95% CI 1.06-1.59). The opposite pattern was confirmed for ulcerative colitis (current smokers protected, former smokers at increased risk). This dichotomy in two diseases that share many features remains one of the most striking environmental epidemiology findings in IBD and points to fundamentally different pathogenic mechanisms despite overlapping clinical phenotype.

Polymeric Diet vs Corticosteroids — Borrelli RCT

Borrelli et al. (2006, PMID 16682258, Clinical Gastroenterology and Hepatology) randomized 37 children with active Crohn's disease to either 10 weeks of exclusive polymeric diet or oral corticosteroids (prednisone tapered over 8 weeks). The primary outcome was clinical remission at week 10 by Pediatric Crohn's Disease Activity Index. Clinical remission rates were 79% in the diet group versus 67% in the steroid group — statistically equivalent. The secondary outcome of mucosal healing assessed by ileocolonoscopy at week 10 favored the polymeric diet: substantially more diet-treated patients had endoscopic improvement or healing than steroid-treated patients. This was one of the first studies to demonstrate that exclusive enteral nutrition produces not just symptom relief but actual histologic mucosal healing, which became a foundation for the now-standard pediatric guideline of EEN as first-line induction therapy.

Omega-3 for Maintenance — Cochrane Review

Lev-Tzion et al. (2014, PMID 24585498, Cochrane Database of Systematic Reviews) systematically reviewed and meta-analyzed six randomized controlled trials of omega-3 fatty acids for maintenance of remission in Crohn's disease, including a combined 1,039 patients. The pooled risk ratio for relapse with omega-3 versus placebo was 0.77 (95% CI 0.61-0.98), suggesting modest benefit, but with substantial heterogeneity (I² = 58%). When the two largest, highest-quality trials (EPIC-1 and EPIC-2) were considered, the apparent benefit attenuated significantly, and the authors concluded that omega-3 fatty acids "are probably ineffective for maintenance of remission" in Crohn's disease. This Cochrane review tempered earlier enthusiasm following smaller trials and remains the most authoritative single source on this question. It is important to note this is a finding about supplemental fish oil for maintaining remission — not about overall dietary fish intake or anti-inflammatory dietary patterns, where the evidence remains favorable.

Vitamin D Treatment — Jorgensen Trial

Jorgensen and colleagues (2010, PMID 20491740, Alimentary Pharmacology and Therapeutics) randomized 94 Crohn's patients in clinical remission to either 1200 IU/day oral vitamin D3 or placebo for 12 months. The primary outcome was clinical relapse. Relapse rates were 13% in the vitamin D group versus 29% in the placebo group — relative risk reduction of approximately 56%. The difference reached the conventional borderline of significance (p=0.06) — likely underpowered given the modest sample. Mean serum 25(OH)D rose from 69 nmol/L to 96 nmol/L in the supplemented group, while remaining unchanged in the placebo group. This trial provides the cleanest single piece of randomized evidence for vitamin D3 supplementation as an adjunct to maintain remission in Crohn's, complementing observational data showing that low serum 25(OH)D is associated with increased disease activity and surgery rates.

Crohn's Disease Exclusion Diet — Sigall-Boneh Cohort

Sigall-Boneh et al. (2014, PMID 24983973, Inflammatory Bowel Diseases) reported on 47 patients (34 children, 13 young adults) with active Crohn's disease treated with the Crohn's Disease Exclusion Diet plus partial enteral nutrition (PEN) for 6 weeks. The CDED restricts animal fat, gluten-containing grains, dairy products other than specific yogurt, emulsifiers, canned and processed foods, and certain other items hypothesized to disrupt the mucus layer and microbial ecology, while permitting specified whole foods and 50% of caloric intake from a polymeric formula. Clinical remission was achieved in 70% of participants at week 6, with significant reductions in inflammatory markers (CRP, calprotectin). Importantly, tolerance was high (compliance 78%), in stark contrast to typical EEN compliance rates in adults, which are often below 50%. This study established proof-of-concept for combining a structured whole-food exclusion diet with partial enteral nutrition.

CDED + PEN vs EEN — Levine RCT

Levine et al. (2019, PMID 31170412, Gastroenterology) conducted a multicenter randomized controlled trial in 78 children with mild-to-moderate active Crohn's disease, comparing 12 weeks of CDED + PEN to standard EEN (6 weeks EEN followed by 6 weeks of PEN with regular diet). At week 6, intent-to-treat clinical remission was 75% with CDED + PEN versus 59% with EEN — a numerically higher rate that was not statistically inferior. Tolerability was dramatically better with CDED + PEN: 97% completed the protocol versus 73% with EEN. By week 12, sustained corticosteroid-free remission was achieved in 75.6% with CDED + PEN versus 45.1% with EEN (p=0.01) — a clinically meaningful advantage favoring the whole-food-plus-PEN approach. Inflammatory markers (CRP, calprotectin) declined in both arms. This trial substantially upgraded the evidence base for whole-food dietary therapy in Crohn's, demonstrating that a structured exclusion diet plus partial enteral nutrition is at least as effective as EEN with much better real-world adherence.

Diet and IBD Risk — Hou Systematic Review

Hou, Abraham, and El-Serag (2011, PMID 21468064, American Journal of Gastroenterology) systematically reviewed 19 studies on diet and the risk of developing inflammatory bowel disease, encompassing more than 2,600 IBD cases and tens of thousands of controls. For Crohn's disease specifically, high intake of saturated fats, total polyunsaturated fatty acids (driven largely by omega-6 vegetable oils), monounsaturated fats, and meat — particularly red and processed meat — was associated with increased risk in most of the included studies. High intake of fiber and fruit was associated with reduced risk. While individual studies varied in design and quality, the directionality across the literature was consistent: a Western dietary pattern raised risk, while traditional plant-rich and Mediterranean-like patterns were protective. This review remains a useful foundation for the dietary advice given to Crohn's patients in remission, though it addresses risk of developing the disease rather than activity in established disease.

Evidence Strength Assessment

The evidence for smoking cessation in Crohn's disease is among the strongest non-pharmacologic interventions in all of IBD: multiple large cohorts, meta-analytic confirmation, and biological plausibility. This should be the first lifestyle conversation with any smoking Crohn's patient.

The evidence for exclusive enteral nutrition in pediatric Crohn's is strong: multiple RCTs, including head-to-head comparisons with corticosteroids, plus mucosal healing data. EEN is now first-line in major pediatric guidelines.

The evidence for CDED + partial enteral nutrition has improved substantially with the Levine 2019 RCT, providing Level I evidence for a whole-food alternative to EEN with better tolerance.

The evidence for vitamin D supplementation for maintenance is moderate: one borderline-significant RCT plus consistent observational data. Correcting documented deficiency is uncontroversial; pharmacologic doses for relapse prevention need larger trials but the risk-benefit ratio is favorable.

The evidence for omega-3 supplementation as a maintenance therapy is, after Cochrane review, weak. Dietary fish remains beneficial as part of an overall anti-inflammatory pattern but supplemental fish oil should not be treated as a maintenance medication.

The evidence for dietary patterns affecting Crohn's risk is moderate-to-strong observational consensus; intervention trials of whole dietary patterns in established disease are growing but still early.